The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer

被引:55
作者
Xiong, Guangbing [1 ,2 ]
Feng, Mengyu [1 ,2 ]
Yang, Gang [1 ,2 ]
Zheng, Suli [1 ,2 ]
Song, Xujun [1 ,2 ]
Cao, Zhe [1 ,2 ]
You, Lei [1 ,2 ]
Zheng, Lianfang [2 ,3 ]
Hu, Ya [1 ,2 ]
Zhang, Taiping [1 ,2 ]
Zhao, Yupei [1 ,2 ]
机构
[1] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Gen Surg, Beijing 100730, Peoples R China
[2] Peking Union Med Coll, Beijing 100730, Peoples R China
[3] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Nucl Med, Beijing 100730, Peoples R China
基金
中国国家自然科学基金;
关键词
Pancreatic cancer; Chemoresistance; microRNA; Long non-coding RNA; Mechanism; PREDICTS POOR-PROGNOSIS; GEMCITABINE RESISTANCE; DUCTAL ADENOCARCINOMA; DOWN-REGULATION; CELL-PROLIFERATION; TUMOR-SUPPRESSOR; GASTRIC-CANCER; UP-REGULATION; INCREASES CHEMORESISTANCE; RIBONUCLEOTIDE REDUCTASE;
D O I
10.1016/j.canlet.2017.02.020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pancreatic cancer, which is often asymptomatic, is currently one of the most common causes of cancer related death. This phenomenon is most likely due to a lack of early diagnosis, a high metastasis rate and a disappointing chemotherapy outcome. Thus, improving treatment outcomes by overcoming chemotherapy resistance may be a useful strategy in pancreatic cancer. Various underlying mechanisms involved in the chemoresistance of pancreatic cancer have been investigated. Notably, non-coding RNAs (ncRNAs), especially microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), play a pivotal role in regulating sensitivity to chemotherapy in pancreatic cancer. In this review, we highlight recent evidence regarding the role of miRNAs and IncRNAs in the chemoresistance of pancreatic cancer, including their expression levels, targets, biological functions and the regulation of chemoresistance, and discuss the potential clinical application of miRNAs and IncRNAs in the treatment of pancreatic cancer. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:94 / 102
页数:9
相关论文
共 151 条
[1]   MicroRNAs as novel targets and tools in cancer therapy [J].
Abba, Mohammed L. ;
Patil, Nitin ;
Leupold, Joerg H. ;
Moniuszko, Marcin ;
Utikal, Jochen ;
Niklinski, Jacek ;
Allgayer, Heike .
CANCER LETTERS, 2017, 387 :84-94
[2]   Tumor-promoting function of single nucleotide polymorphism rs1836724 (C3388T) alters multiple potential legitimate microRNA binding sites at the 3′-untranslated region of ErbB4 in breast cancer [J].
Bagheri, Fatemeh ;
Tanha, Hamzeh Mesrian ;
Naeini, Marjan Mojtabavi ;
Ghaedi, Kamran ;
Azadeh, Mansoureh .
MOLECULAR MEDICINE REPORTS, 2016, 13 (05) :4494-4498
[3]   Epigenetic regulation of microRNA expression in colorectal cancer [J].
Bandres, Eva ;
Agirre, Xabier ;
Bitarte, Nerea ;
Ramirez, Natalia ;
Zarate, Ruth ;
Roman-Gomez, Jose ;
Prosper, Felipe ;
Garcia-Foncillas, Jesus .
INTERNATIONAL JOURNAL OF CANCER, 2009, 125 (11) :2737-2743
[4]   p53-dependent Induction of PVT1 and miR-1204 [J].
Barsotti, Anthony M. ;
Beckerman, Rachel ;
Laptenko, Oleg ;
Huppi, Konrad ;
Caplen, Natasha J. ;
Prives, Carol .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (04) :2509-2519
[5]   RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform [J].
Bennett, C. Frank ;
Swayze, Eric E. .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2010, 50 :259-293
[6]   Knockdown of microRNA-21 Inhibits Proliferation and Increases Cell Death by Targeting Programmed Cell Death 4 (PDCD4) in Pancreatic Ductal Adenocarcinoma [J].
Bhatti, Imran ;
Lee, Andrew ;
James, Victoria ;
Hall, Richard I. ;
Lund, Jonathan N. ;
Tufarelli, Cristina ;
Lobo, Dileep N. ;
Larvin, Michael .
JOURNAL OF GASTROINTESTINAL SURGERY, 2011, 15 (01) :199-208
[7]   Gemcitabine resistance in pancreatic ductal adenocarcinoma [J].
Binenbaum, Yoav ;
Na'ara, Shorook ;
Gil, Ziv .
DRUG RESISTANCE UPDATES, 2015, 23 :55-68
[8]   Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer [J].
Boeck, S. ;
Hoehler, T. ;
Seipelt, G. ;
Mahlberg, R. ;
Wein, A. ;
Hochhaus, A. ;
Boeck, H. -P. ;
Schmid, B. ;
Kettner, E. ;
Stauchlo, M. ;
Lordick, F. ;
Ko, Y. ;
Geissler, M. ;
Schoppmeyer, K. ;
Kojouharoff, G. ;
Golf, A. ;
Neugebauer, S. ;
Heinemann, V. .
ANNALS OF ONCOLOGY, 2008, 19 (02) :340-347
[9]   miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2 [J].
Cai, Baobao ;
An, Yong ;
Lv, Nan ;
Chen, Jianmin ;
Tu, Min ;
Sun, Jie ;
Wu, Pengfei ;
Wei, Jishu ;
Jiang, Kuirong ;
Miao, Yi .
ONCOLOGY REPORTS, 2013, 29 (05) :1769-1776
[10]  
Cavalcante LD, 2014, EUR J PHARMACOL, V741, P8, DOI [10.1010/j.ejphar.2014.07.041, 10.1016/j.ejphar.2014.07.041]